Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Gross Profit: 2021-2025

Historic Gross Profit for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to $45.8 million.

  • Rhythm Pharmaceuticals' Gross Profit rose 55.66% to $45.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.9 million, marking a year-over-year increase of 56.30%. This contributed to the annual value of $116.8 million for FY2024, which is 71.39% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Gross Profit of $45.8 million as of Q3 2025, which was up 6.61% from $43.0 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Gross Profit ranged from a high of $45.8 million in Q3 2025 and a low of $31,000 during Q1 2021.
  • In the last 3 years, Rhythm Pharmaceuticals' Gross Profit had a median value of $26.1 million in 2024 and averaged $27.5 million.
  • Data for Rhythm Pharmaceuticals' Gross Profit shows a peak YoY soared of 6,241.61% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Gross Profit stood at $1.6 million in 2021, then surged by 390.96% to $7.8 million in 2022, then soared by 170.56% to $21.0 million in 2023, then surged by 81.15% to $38.0 million in 2024, then skyrocketed by 55.66% to $45.8 million in 2025.
  • Its Gross Profit stands at $45.8 million for Q3 2025, versus $43.0 million for Q2 2025 and $29.1 million for Q1 2025.